25 Years of Revolutionary Microplate Reader Technology at the LS2
News Dec 16, 2014
BMG LABTECH, the Microplate Reader Company is Gold sponsor of the LS² Annual Meeting 2015 from January 29-30th in Zurich. A visit to booth #33 at the Campus Irchel of the University of Zurich promises a personal introduction to BMG LABTECH’s high performance microplate readers and latest innovations.
Since its establishment in Offenburg, Germany BMG LABTECH has become a world leader in microplate reading due to continuous development of innovative and unique technologies.
25 successful years in the industry attest the quality and reliability of BMG LABTECH’s products and services. BMG LABTECH will showcase the CLARIOstar® with new Atmospheric Control Unit (ACU) and POLARstar® Omega, at the LS2 Annual Meeting 2015 in Zurich, booth #33.
The CLARIOstar® multimode microplate reader offers filter-like performance with advanced LVF Monochromators™ that provides increased sensitivity over conventional monochromators.
The LVF Monochromators™, along with filters and an UV/ Vis spectrometer can be used for a variety of applications in up to eight different detection modes. With its new Atmospheric Control Unit the CLARIOstar® is able to provide the physiological environment for any cell type, enhancing cell-based microplate assays.
The POLARstar® Omega is equipped with an ultra-fast UV/Vis spectrometer and simultaneous dual emission, representing the best combination of performance and flexibility for all life science applications.
The POLARstar® Omega meets the requirements of RT-QuIC seeding assays as it is very robust and the transport system can handle harsh settings, such as long periods of high-speed shaking.
Chemical Compound Class Possesses Potential for Treating Zika VirusNews
A new and promising class of chemical compounds has major potential for treating Zika virus and respiratory syncytial virus, or RSV, according to a new study.READ MORE
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE